-
Je něco špatně v tomto záznamu ?
Pulmonary thromboembolism in congenital heart defects with severe pulmonary arterial hypertension
Monika Kaldarárová, Iveta Šimková, Tatiana Valkovičová, Anna Remková, Vladimír Neuschl
Jazyk angličtina Země Česko
NLK
Elsevier Open Access Journals
od 2012-01-01 do 2018-12-31
ROAD: Directory of Open Access Scholarly Resources
od 2006
- MeSH
- antikoagulancia terapeutické užití MeSH
- arteria pulmonalis patologie MeSH
- Aspirin terapeutické užití MeSH
- cyanóza MeSH
- dilatace patologická MeSH
- dospělí MeSH
- Eisenmengerův syndrom farmakoterapie patofyziologie patologie MeSH
- koagulopatie diagnóza etiologie farmakoterapie patologie MeSH
- krvácení prevence a kontrola MeSH
- lidé středního věku MeSH
- lidé MeSH
- plicní embolie * etiologie farmakoterapie patologie prevence a kontrola MeSH
- plicní hypertenze * patofyziologie patologie MeSH
- prospektivní studie MeSH
- rizikové faktory MeSH
- senioři MeSH
- vrozené srdeční vady * etiologie farmakoterapie patologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
Congenital heart defect (CHD) with shunt can lead to severe, even irreversible pulmonary arterial hypertension (PAH); in extreme form to Eisenmenger syndrome (ES). Despite relatively good long-term survival, these patients often suffer from cyanosis and multisystemic dysfunction, where pulmonary artery thrombosis can be a potentially fatal complication. Together with bleeding these are the most frequent causes of non-cardiac death in patients with severe PAH due to CHD.Patients and methodsProspective study of 40 patients with severe PAH due to CHD (28 female/12 male, median age 41.5 years) was performed, with the aim to analyze the presence of pulmonary artery thrombosis and correlating anatomical and laboratory risk factors.ResultsPrevious thrombosis and/or thromboembolic event was found in 7 patients (17.5%). Significant differences in cyanotic vs non-cyanotic patients were in red blood count parameters: median hemoglobin level 195 vs 141 (p<0.0001), median erythrocytes count 6.62 vs 4.88×1012/l (p<0.0001), median hematocrit 0.58 vs 0.44 (p<0.0001). Laboratory findings causing increased risk for thrombosis were increased thrombocytes aggregation in 15 patients (37.5%), hypercoagulation in 5 patients (12.5%) and endothelial dysfunction in 8 patients (20%). Anatomical risk factor—severe pulmonary artery dilatation (>40 mm in female and >45 mm in male) was found in 19 patients (51.4%).ConclusionsPatients with severe PAH due to CHD represent a high-risk group for pulmonary artery thrombosis with morphological and flow pathology combined with secondary erythrocytosis and coagulation abnormalities. A relatively high incidence of platelet hyperaggregability shown in our study would propose that aspirin therapy might be considered in some highly selected patients with severe PAH due to CHD. Further studies though are needed to support this data.
Centrum hemostázy a trombózy HemoMedika Bratislava Slovenská republika
Inštitút zobrazovacej diagnostiky Trnava Slovenská republika
Národný ústav srdcových a cievnych chorôb a s Detské kardiocentrum Bratislava Slovenská republika
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13021653
- 003
- CZ-PrNML
- 005
- 20130809142537.0
- 007
- ta
- 008
- 130611s2013 xr da f 000 0eng||
- 009
- AR
- 024 7_
- $2 doi $a 10.1016/j.crvasa.2013.03.006
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng $b slo
- 044 __
- $a xr
- 100 1_
- $a Kaldarárová, Monika. $7 xx0320891 $u Národný ústav srdcových a cievnych chorôb, a. s. – Detské kardiocentrum, Bratislava, Slovenská republika
- 245 10
- $a Pulmonary thromboembolism in congenital heart defects with severe pulmonary arterial hypertension / $c Monika Kaldarárová, Iveta Šimková, Tatiana Valkovičová, Anna Remková, Vladimír Neuschl
- 520 9_
- $a Congenital heart defect (CHD) with shunt can lead to severe, even irreversible pulmonary arterial hypertension (PAH); in extreme form to Eisenmenger syndrome (ES). Despite relatively good long-term survival, these patients often suffer from cyanosis and multisystemic dysfunction, where pulmonary artery thrombosis can be a potentially fatal complication. Together with bleeding these are the most frequent causes of non-cardiac death in patients with severe PAH due to CHD.Patients and methodsProspective study of 40 patients with severe PAH due to CHD (28 female/12 male, median age 41.5 years) was performed, with the aim to analyze the presence of pulmonary artery thrombosis and correlating anatomical and laboratory risk factors.ResultsPrevious thrombosis and/or thromboembolic event was found in 7 patients (17.5%). Significant differences in cyanotic vs non-cyanotic patients were in red blood count parameters: median hemoglobin level 195 vs 141 (p<0.0001), median erythrocytes count 6.62 vs 4.88×1012/l (p<0.0001), median hematocrit 0.58 vs 0.44 (p<0.0001). Laboratory findings causing increased risk for thrombosis were increased thrombocytes aggregation in 15 patients (37.5%), hypercoagulation in 5 patients (12.5%) and endothelial dysfunction in 8 patients (20%). Anatomical risk factor—severe pulmonary artery dilatation (>40 mm in female and >45 mm in male) was found in 19 patients (51.4%).ConclusionsPatients with severe PAH due to CHD represent a high-risk group for pulmonary artery thrombosis with morphological and flow pathology combined with secondary erythrocytosis and coagulation abnormalities. A relatively high incidence of platelet hyperaggregability shown in our study would propose that aspirin therapy might be considered in some highly selected patients with severe PAH due to CHD. Further studies though are needed to support this data.
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a vrozené srdeční vady $x etiologie $x farmakoterapie $x patologie $7 D006330
- 650 12
- $a plicní hypertenze $x patofyziologie $x patologie $7 D006976
- 650 _2
- $a arteria pulmonalis $x patologie $7 D011651
- 650 _2
- $a dilatace patologická $7 D004108
- 650 _2
- $a cyanóza $7 D003490
- 650 _2
- $a Eisenmengerův syndrom $x farmakoterapie $x patofyziologie $x patologie $7 D004541
- 650 12
- $a plicní embolie $x etiologie $x farmakoterapie $x patologie $x prevence a kontrola $7 D011655
- 650 _2
- $a krvácení $x prevence a kontrola $7 D006470
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a antikoagulancia $x terapeutické užití $7 D000925
- 650 _2
- $a Aspirin $x terapeutické užití $7 D001241
- 650 _2
- $a koagulopatie $x diagnóza $x etiologie $x farmakoterapie $x patologie $7 D001778
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 700 1_
- $a Šimková, Iveta. $7 jx20120222045 $u Kardiologická klinika Slovenskej zdravotníckej univerzity a Národného ústavu srdcových a cievnych chorôb, a. s., Bratislava, Slovenská republika
- 700 1_
- $a Valkovičová, Tatiana. $7 _AN073351 $u Kardiologická klinika Slovenskej zdravotníckej univerzity a Národného ústavu srdcových a cievnych chorôb, a. s., Bratislava, Slovenská republika
- 700 1_
- $a Remková, Anna, $d 1954- $7 nlk20050173079 $u Centrum hemostázy a trombózy HemoMedika, Bratislava, Slovenská republika
- 700 1_
- $a Neuschl, Vladimír. $7 _AN073352 $u Inštitút zobrazovacej diagnostiky, Trnava, Slovenská republika
- 773 0_
- $t Cor et vasa $x 0010-8650 $g Roč. 55, č. 2 (2013), s. 209-214 (e e170-e175) $w MED00010972
- 910 __
- $a ABA008 $b A 2980 $c 438 $y 3 $z 0
- 990 __
- $a 20130424185703 $b ABA008
- 991 __
- $a 20130809143039 $b ABA008
- 999 __
- $a ok $b bmc $g 985244 $s 820008
- BAS __
- $a 3
- BMC __
- $a 2013 $b 55 $c 2 $d 209-214 $f e170-e175 $i 0010-8650 $m Cor et Vasa (Brno) $n Cor Vasa (Brno Print) $x MED00010972
- LZP __
- $c NLK121 $d 20130809 $a NLK 2013-31/vt